Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Shawn O'Connor

Shawn O'Connor

Chief Executive Officer, Simulations Plus

Appears in 1 story

Notable Quotes

O'Connor cited funding uncertainty, drug-pricing pressure, and possible tariffs as headwinds pushing pharma clients to cut budgets and cancel projects.

Stories

Altaris takes drug-simulation software maker Simulations Plus private

Money Moves

Leading the company through the sale to Altaris

Simulations Plus has traded on the Nasdaq stock market since 2004. On June 16, 2026, it agreed to leave public markets. The healthcare investment firm Altaris will buy the drug-simulation software maker for about $375 million and take it private.

Updated Yesterday